Error message

EDS Server Issue
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Amsterdam] : Elsevier B.V., [2014]-
    • Subject Terms:
    • Abstract:
      Background: Long non-coding RNAs (lncRNAs) show great potential as diagnostic tools in many diseases. We aimed to develop sensitive and noninvasive biomarkers in saliva for detecting early hepatocellular carcinoma (HCC).
      Methods: Candidate lncRNA biomarkers identified by Agilent microarray were subjected to validation using qPCR for the quantification of their expression levels in independent tissue, plasma and saliva sample sets, including healthy controls, HBsAg carriers, patients with chronic Hepatitis B, liver cirrhosis, early HCC, and advanced HCC. Levels of candidate biomarkers were also measured in totally 108 saliva samples from patients with any one of other nine leading causes of cancer death in men and women.
      Findings: Lnc-PCDH9-13:1 was significantly elevated in HCC tissues, plasma and saliva of HCC patients compared with healthy controls and groups of several benign liver diseases and other leading cancers. Its level was significantly reduced after curative hepatectomy but significantly elevated again if HCC recurrence occurred. Salivary lnc-PCDH9-13:1 showed reasonable specificities and sensitivities for detecting HCC compared with several control groups. Furthermore, the overexpression of lnc-PCDH9-13:1 promotes cell proliferation and migration in vitro.
      Interpretation: Salivary lnc-PCDH9-13:1 is a desirable biomarker for early HCC. It may help warrant prospective validation with larger sample sizes in multi-centers.
      (Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.)
    • References:
      Hepatology. 2011 Mar;53(3):1020-2. (PMID: 21374666)
      Nat Clin Pract Oncol. 2007 Jul;4(7):424-32. (PMID: 17597707)
      CA Cancer J Clin. 2018 Jan;68(1):7-30. (PMID: 29313949)
      Nat Commun. 2015 Jun 16;6:7369. (PMID: 26077142)
      PLoS One. 2010 Oct 20;5(10):e13515. (PMID: 20976003)
      Cancer Prev Res (Phila). 2015 Feb;8(2):165-73. (PMID: 25538087)
      BMJ. 2003 Jan 4;326(7379):41-4. (PMID: 12511463)
      Biomarkers. 2011 Sep;16(6):498-503. (PMID: 21854254)
      Adv Exp Med Biol. 2015;867:179-93. (PMID: 26530367)
      Gut. 2013 Dec;62(12):1692-703. (PMID: 23092766)
      Am J Respir Crit Care Med. 2014 Nov 15;190(10):1117-26. (PMID: 25317990)
      Liver Transpl. 2004 Feb;10(2 Suppl 1):S39-45. (PMID: 14762838)
      Med Oncol. 2017 Jan;34(1):7. (PMID: 27943101)
      J Am Dent Assoc. 2012 Oct;143(10 Suppl):19S-24S. (PMID: 23034834)
      Oncotarget. 2016 May 3;7(18):25408-19. (PMID: 27028998)
      Analyst. 2016 Jan 21;141(2):393-402. (PMID: 26645892)
      Chin Med J (Engl). 2007 Dec 20;120(24):2157-8. (PMID: 18167195)
      J Appl Genet. 2017 May;58(2):231-237. (PMID: 27910062)
      Biol Res Nurs. 2017 Mar;19(2):153-161. (PMID: 27605566)
      CA Cancer J Clin. 2015 Mar;65(2):87-108. (PMID: 25651787)
      Mol Cancer. 2015 Jan 21;14:3. (PMID: 25608466)
      World J Hepatol. 2015 Jun 18;7(11):1541-52. (PMID: 26085913)
      Biomark Cancer. 2016 Jul 04;8(Suppl 1):37-55. (PMID: 27398029)
      Chin Med J (Engl). 1993 Mar;106(3):179-82. (PMID: 7686840)
      PLoS One. 2015 Jun 29;10(6):e0130996. (PMID: 26121640)
      Hepatol Int. 2009 Jun;3(2):323-33. (PMID: 19669358)
      J Virol Methods. 2013 Dec;194(1-2):46-51. (PMID: 23969313)
      J Viral Hepat. 2004 Mar;11(2):97-107. (PMID: 14996343)
      J Surg Oncol. 2018 Mar;117(4):644-650. (PMID: 29127719)
      Hepatology. 2000 Feb;31(2):330-5. (PMID: 10655254)
    • Contributed Indexing:
      Keywords: Biomarker; Early diagnosis; Hepatocellular carcinoma; Long non-coding RNA; Saliva
    • Accession Number:
      0 (Biomarkers, Tumor)
      0 (RNA, Long Noncoding)
    • Publication Date:
      Date Created: 20180727 Date Completed: 20181107 Latest Revision: 20181114
    • Publication Date:
      20200827
    • Accession Number:
      PMC6085584
    • Accession Number:
      10.1016/j.ebiom.2018.06.026
    • Accession Number:
      30045829
  • Citations
    • ABNT:
      XIE, Z. et al. Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma. EBioMedicine, [s. l.], v. 33, p. 57–67, 2018. DOI 10.1016/j.ebiom.2018.06.026. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdc&AN=30045829. Acesso em: 20 out. 2020.
    • AMA:
      Xie Z, Zhou F, Yang Y, et al. Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma. EBioMedicine. 2018;33:57-67. doi:10.1016/j.ebiom.2018.06.026
    • APA:
      Xie, Z., Zhou, F., Yang, Y., Li, L., Lei, Y., Lin, X., Li, H., Pan, X., Chen, J., Wang, G., Liu, H., Jiang, J., & Wu, B. (2018). Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma. EBioMedicine, 33, 57–67. https://doi.org/10.1016/j.ebiom.2018.06.026
    • Chicago/Turabian: Author-Date:
      Xie, Zijun, Fangyuan Zhou, Yidong Yang, Leijia Li, Yiming Lei, Xianyi Lin, Haijiao Li, et al. 2018. “Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma.” EBioMedicine 33 (July): 57–67. doi:10.1016/j.ebiom.2018.06.026.
    • Harvard:
      Xie, Z. et al. (2018) ‘Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma’, EBioMedicine, 33, pp. 57–67. doi: 10.1016/j.ebiom.2018.06.026.
    • Harvard: Australian:
      Xie, Z, Zhou, F, Yang, Y, Li, L, Lei, Y, Lin, X, Li, H, Pan, X, Chen, J, Wang, G, Liu, H, Jiang, J & Wu, B 2018, ‘Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma’, EBioMedicine, vol. 33, pp. 57–67, viewed 20 October 2020, .
    • MLA:
      Xie, Zijun, et al. “Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma.” EBioMedicine, vol. 33, July 2018, pp. 57–67. EBSCOhost, doi:10.1016/j.ebiom.2018.06.026.
    • Chicago/Turabian: Humanities:
      Xie, Zijun, Fangyuan Zhou, Yidong Yang, Leijia Li, Yiming Lei, Xianyi Lin, Haijiao Li, et al. “Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma.” EBioMedicine 33 (July 2018): 57–67. doi:10.1016/j.ebiom.2018.06.026.
    • Vancouver/ICMJE:
      Xie Z, Zhou F, Yang Y, Li L, Lei Y, Lin X, et al. Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma. EBioMedicine [Internet]. 2018 Jul [cited 2020 Oct 20];33:57–67. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdc&AN=30045829